MedTrace Logo

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

NCT07016490 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-01-28

No results posted yet for this study

Summary

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

SSGJ-709

A bispecific antibody targeting PD-1 and LAG-3.

Sponsors & Collaborators

  • Macquarie University, Australia

    collaborator OTHER

  • Shenyang Sunshine Pharmaceutical Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Andrew Parsonson · Macquarie University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2027-09-30
Completion
2027-12-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07016490 on ClinicalTrials.gov